百利天恒：注射用BL-M24D1（ADC）治疗复发或难治性血液系统恶性肿瘤和晚期实体瘤获药物临床试验批准

Core Viewpoint - The company has received formal approval from the National Medical Products Administration (NMPA) for the clinical trial of its innovative biopharmaceutical, BL-M24D1, which is an antibody-drug conjugate (ADC) targeting relapsed or refractory hematologic malignancies and advanced solid tumors [1] Group 1 - The clinical trial approval is for the company's self-developed ADC drug, BL-M24D1, which incorporates a new generation toxin [1] - BL-M24D1 is developed from the same small molecule technology platform as BL-B16D1 and BL-M17D1, sharing the same "linker + toxin" platform [1] - The indications for BL-M24D1 include relapsed or refractory hematologic malignancies and advanced solid tumors [1]